Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Jan;22(1):9-17.
doi: 10.1177/0218492312464035. Epub 2013 Jul 9.

CardiaMed mechanical valve: mid-term results of a multicenter clinical trial

Affiliations
Clinical Trial

CardiaMed mechanical valve: mid-term results of a multicenter clinical trial

Vladimir M Nazarov et al. Asian Cardiovasc Thorac Ann. 2014 Jan.

Abstract

Background: Prosthesis choice is a major concern in valvular surgery.

Methods: A multicenter clinical trial was performed to assess the efficacy and safety of the CardiaMed prosthetic heart valve. The study enrolled 420 patients who underwent mitral (209) or aortic (211) valve replacement from 2003 to 2004 at 7 institutions in Russia, and who were followed up from 2006 to 2011. The mean age was 52.2 ± 10.2 years (range, 12-78 years), 47.4% were female, and 99.05% completed the study.

Results: The maximum observation term was 7.5 years (2188.5 patient-years); 1081.6 patient-years for aortic and 1106.9 patient-years for mitral valve replacement. The overall 7-year survival rate was 85.1% ± 3.7%; 86.1% ± 4.8% and 84.4% ± 5.4% for aortic and mitral valve replacement, respectively. The 7-year freedom from valve-related death was 93.9% ± 3.7% and 94.5% ± 3.2% for aortic and mitral valve replacement, respectively. When early mortality (<30 days) was excluded, these rates were 94.8% ± 3.1% and 93.8% ± 3.82%, respectively. Linearized valve-dependent complication rates were determined for structural valve failure (0%/patient-year overall), thrombosis (0.63%/patient-year, all for mitral valve replacement), thromboembolic complications including transient neurologic deficits (0.13%/patient-year overall, 0.5%/patient-year for aortic valve replacement, 0.8%/patient-year for mitral valve replacement), hemorrhagic bleeding (0.64%/patient-year overall, 0.55%/patient-year for aortic valve replacement, 0.09%/patient-year for mitral valve replacement), prosthetic endocarditis (0.28%/patient-year overall, 0.28%/patient-year for aortic valve replacement, 0%/patient-year for mitral valve replacement), and hemolysis (0%/patient-year overall).

Conclusion: The CardiaMed mechanical heart valve prostheses meets world standards of safety and efficacy.

Keywords: Aortic valve; follow-up studies; heart valve prosthesis; heart valve prosthesis implantation; mitral valve.

PubMed Disclaimer

Similar articles

Cited by

  • The role of robotics in cardiac surgery: a systematic review.
    Doulamis IP, Spartalis E, Machairas N, Schizas D, Patsouras D, Spartalis M, Tsilimigras DI, Moris D, Iliopoulos DC, Tzani A, Dimitroulis D, Nikiteas NI. Doulamis IP, et al. J Robot Surg. 2019 Feb;13(1):41-52. doi: 10.1007/s11701-018-0875-5. Epub 2018 Sep 25. J Robot Surg. 2019. PMID: 30255360

MeSH terms

LinkOut - more resources